OET conducts Kerala workshop series to strengthen healthcare communication training

Three-city educator training programme equips teachers with practical strategies to improve healthcare English instruction and prepare professionals for global workforce demands

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

Blacksmith Medicines and Zoetis collaborate for novel animal health antibiotics

Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock

Syngene signs 10-year biologics manufacturing agreement with Zoetis

Syngene's collaboration with Zoetis started in 2011

Bristol Myers Squibb wins EU nod for Sotyktu in active psoriatic arthritis

The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio

Lonza launches Singapore Media Development Lab to cut biomanufacturing risk

The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes

FDA nod to Bristol Myers Squibb’s Sotyktu as new oral therapy for psoriatic arthritis

The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials

Avient introduces non-PFAS GlideTech formulations for catheters

GlideTech materials are available in several standard base resins and offer customization options for specific applications

FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA

The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement

BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions